ASCO 2023 | Challenges with administering cellular therapies in patients with T-cell malignancies
LaQuisa Hill, MD, Baylor College of Medicine, Houston, TX, discusses challenges associated with administering cellular therapies in patients with T-cell malignancies. Dr Hill explains that many candidates for autologous T-cell therapy are heavily pretreated and the quality of their T-cells may be reduced. To overcome this challenge, Dr Hill highlights the potential use of NK cells or allogeneic T-cells, and further notes the benefits of creating a bank of T-cells from healthy donors. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
